Image of Carole Mitnick

Carole Diane Mitnick, Sc.D.

Dr. Mitnick graduated cum laude from the University of Rochester in 1988 with a B.A. in political science and French. She spent 1986-1987 in Paris, France, studying at L’Institut d’Etudes Politiques and L’Université de Paris IV. In 1996, she received a masters in international health epidemiology and ecology from the Harvard School of Public Health, and in 2001 she completed a doctor of science degree in international health epidemiology and ecology, also at the Harvard School of Public Health.

Dr. Mitnick’s research centers on the improvement of clinical management and programmatic policy for tuberculosis and multidrug-resistant tuberculosis (MDR-TB) globally. Dr. Mitnick is a founding investigator of a movement to conduct randomized controlled clinical trials to improve treatment of drug-resistant TB (RESIST-TB). Dr. Mitnick’s work also includes applying marginal structural modeling to MDR-TB treatment data to assess the effect on outcomes of different types of therapy in observational studies. Dr. Mitnick is the principal investigator of an NIAID grant to plan a Phase II clinical trial examining the potential of high-dose rifampin to shorten standard TB therapy. Her research questions are strongly influenced by the mission of Partners In Health, with which Dr. Mitnick has worked since 1996: she strives to conduct research that will effect changes in global policy to ensure the highest standard of care and best treatment outcomes for patients suffering from all forms of tuberculosis, regardless of where they live.

This influence has also driven Dr. Mitnick’s involvement in global policy efforts. She contributed to the original and revised Guidelines for the Programmatic Management of MDR-TB. She sought, through the publication, Randomized trials to optimize treatment of MDR-TB: the time for action is now (PLoS Medicine, 2007), to generate increased support for controlled examination of anti-mycobacterial agents for the treatment of MDR-TB. Through participation in working groups, sub-groups, and task forces of the STOP-TB Partnership, she has co-authored two articles which define research agendas for MDR-TB (Gupta et al., IJTLD, 2003; Cobelens et al., PLoS Medicine 2008) and one that proposed standardized definitions for analysis of MDR-TB treatment outcomes (Laserson et al., IJTLD, 2005). She consults for the Green Light Committee of the World Health Organization for francophone countries implementing programmatic management of MDR-TB. Her efforts extend to capacity building for recording and reporting on the management of drug-resistant TB, as well as to clinical and operational research in Latin America and beyond. She develops and participates in post-graduate trainings, network-building activities, and trial protocols to be implemented within settings of national TB programs around the world.

Global Cash Flows for Sustainable Development: A Case Study of Accountability and Health Systems Strengthening in Lesotho.
Authors: Authors: Mukherjee J, Lindeborg MM, Wijayaratne S, Mitnick C, Farmer PE, Satti H.
J Health Care Poor Underserved
View full abstract on Pubmed
Development assistance for community health workers in 114 low- and middle-income countries, 2007-2017.
Authors: Authors: Lu C, Palazuelos D, Luan Y, Sachs SE, Mitnick CD, Rhatigan J, Perry HB.
Bull World Health Organ
View full abstract on Pubmed
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
Authors: Authors: Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B.
Am J Respir Crit Care Med
View full abstract on Pubmed
Disrupting a cycle of mistrust: A constructivist grounded theory study on patient-provider trust in TB care.
Authors: Authors: Law S, Daftary A, Mitnick CD, Dheda K, Menzies D.
Soc Sci Med
View full abstract on Pubmed
Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study.
Authors: Authors: Becerra MC, Huang CC, Lecca L, Bayona J, Contreras C, Calderon R, Yataco R, Galea J, Zhang Z, Atwood S, Cohen T, Mitnick CD, Farmer P, Murray M.
BMJ
View full abstract on Pubmed
Value of observational data for multidrug-resistant tuberculosis.
Authors: Authors: Rodriguez CA, Mitnick CD, Franke MF.
Lancet Infect Dis
View full abstract on Pubmed
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
Authors: Authors: Khan U, Huerga H, Khan AJ, Mitnick CD, Hewison C, Varaine F, Bastard M, Rich M, Franke MF, Atwood S, Khan PY, Seung KJ.
BMC Infect Dis
View full abstract on Pubmed
Causal inference in tuberculosis treatment studies: bias considerations and data needs.
Authors: Authors: Franke MF, Rodriguez CA, Mitnick CD.
Int J Tuberc Lung Dis
View full abstract on Pubmed
Reply to te Brake et al.: Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.
Authors: Authors: Velásquez GE, Brooks MB, Coit JM, Sánchez Garavito E, Calderón RI, Jiménez J, Tintaya K, Peloquin CA, Osso E, Lecca L, Davies GR, Mitnick CD.
Am J Respir Crit Care Med
View full abstract on Pubmed
Tuberculosis active case-finding: more than just finding cases.
Authors: Authors: Mitnick CD, Yuen CM.
Lancet Infect Dis
View full abstract on Pubmed